tovorafenib,day101
day one biopharmaceutical
['tovorafenib', 'firefly-1', 'day one ', 'dayone']
today at #asco23, we presented new data from the registrational phase 2 firefly-1 trial for relapsed or progressive pediatric low grade glioma (plgg). we also announced the initiation of a rolling nda submission for tovorafenib in may 2023. learn more: 
We are a new biotech company focused on developing new cancer therapies for patients of all ages.